资讯

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results And Corporate Highlights
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y22 ...
PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results ...
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from ...